ID   OCI-Ly13.1
AC   CVCL_M072
SY   OCI-LY13.1; OCI-Ly 13-1
DR   Cell_Model_Passport; SIDM01881
DR   Wikidata; Q54931763
RX   PubMed=3567358;
RX   PubMed=8574164;
CC   From: Ontario Cancer Institute (OCI); Toronto; Canada.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_8797 ! OCI-Ly13.2
SX   Female
AG   28Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 29-06-23; Version: 11
//
RX   PubMed=3567358; DOI=10.1182/blood.V69.5.1307.1307;
RA   Tweeddale M.E., Lim B., Jamal N., Robinson J., Zalcberg J.R.,
RA   Lockwood G., Minden M.D., Messner H.A.;
RT   "The presence of clonogenic cells in high-grade malignant lymphoma: a
RT   prognostic factor.";
RL   Blood 69:1307-1314(1987).
//
RX   PubMed=8574164; DOI=10.3109/10428199509059672;
RA   Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.;
RT   "p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's
RT   lymphoma cell lines.";
RL   Leuk. Lymphoma 19:165-171(1995).
//